JP7844430B2 - 抗ｇｐｒｃ５ｄ抗体に対する抗イディオタイプ抗体 - Google Patents

抗ｇｐｒｃ５ｄ抗体に対する抗イディオタイプ抗体

Info

Publication number
JP7844430B2
JP7844430B2 JP2023503042A JP2023503042A JP7844430B2 JP 7844430 B2 JP7844430 B2 JP 7844430B2 JP 2023503042 A JP2023503042 A JP 2023503042A JP 2023503042 A JP2023503042 A JP 2023503042A JP 7844430 B2 JP7844430 B2 JP 7844430B2
Authority
JP
Japan
Prior art keywords
antigen
seq
amino acid
binding moiety
antibody
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2023503042A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023535684A5 (enExample
JP2023535684A (ja
Inventor
チー，エレン
エドワーズ，ウィルソン
フソブスキ，マット
ラコンブ，アン
マルティネス，クリスチャン
ミミ ジョウ，ホン
リー，ジョン，ティー．
Original Assignee
ヤンセン バイオテツク，インコーポレーテツド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ヤンセン バイオテツク，インコーポレーテツド filed Critical ヤンセン バイオテツク，インコーポレーテツド
Publication of JP2023535684A publication Critical patent/JP2023535684A/ja
Publication of JP2023535684A5 publication Critical patent/JP2023535684A5/ja
Application granted granted Critical
Publication of JP7844430B2 publication Critical patent/JP7844430B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/42—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against immunoglobulins
    • C07K16/4283—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an allotypic or isotypic determinant on Ig
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/567—Framework region [FR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Food Science & Technology (AREA)
  • Cell Biology (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
JP2023503042A 2020-07-17 2021-07-15 抗ｇｐｒｃ５ｄ抗体に対する抗イディオタイプ抗体 Active JP7844430B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202063053286P 2020-07-17 2020-07-17
US63/053,286 2020-07-17
PCT/IB2021/056418 WO2022013819A1 (en) 2020-07-17 2021-07-15 Anti-idiotypic antibodies against anti-gprc5d antibodies

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2026057713A Division JP2026129698A (ja) 2020-07-17 2026-03-31 抗ｇｐｒｃ５ｄ抗体に対する抗イディオタイプ抗体

Publications (3)

Publication Number Publication Date
JP2023535684A JP2023535684A (ja) 2023-08-21
JP2023535684A5 JP2023535684A5 (enExample) 2024-06-25
JP7844430B2 true JP7844430B2 (ja) 2026-04-13

Family

ID=77499865

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023503042A Active JP7844430B2 (ja) 2020-07-17 2021-07-15 抗ｇｐｒｃ５ｄ抗体に対する抗イディオタイプ抗体

Country Status (7)

Country Link
US (1) US12030937B2 (enExample)
EP (1) EP4225801A1 (enExample)
JP (1) JP7844430B2 (enExample)
CN (1) CN115884987A (enExample)
CA (1) CA3189562A1 (enExample)
IL (1) IL299894A (enExample)
WO (1) WO2022013819A1 (enExample)

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2019527061A (ja) 2016-07-20 2019-09-26 ヤンセン ファーマシューティカ エヌ．ベー． 抗ｇｐｒｃ５ｄ抗体、ｇｐｒｃ５ｄとｃｄ３を結合する二重特異性抗原結合分子、及びその使用
WO2020148677A1 (en) 2019-01-18 2020-07-23 Janssen Biotech, Inc. Gprc5d chimeric antigen receptors and cells expressing the same

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
ES2246502T3 (es) 1990-08-29 2006-02-16 Genpharm International, Inc. Animales no humanos transgenicos capaces de producir anticuerpos heterologos.
US6265150B1 (en) 1995-06-07 2001-07-24 Becton Dickinson & Company Phage antibodies
US5714352A (en) 1996-03-20 1998-02-03 Xenotech Incorporated Directed switch-mediated DNA recombination
WO2001058479A1 (en) 2000-02-08 2001-08-16 The Penn State Research Foundation Immunotherapy using interleukin 13 receptor subunit alpha 2
JP5838021B2 (ja) 2005-04-15 2015-12-24 マクロジェニクス，インコーポレーテッド 共有結合型ダイアボディとその使用
US9963510B2 (en) 2005-04-15 2018-05-08 Macrogenics, Inc. Covalent diabodies and uses thereof
AU2008343589A1 (en) 2007-12-19 2009-07-09 Centocor Ortho Biotech Inc. Design and generation of human de novo pIX phage display libraries via fusion to pIX or pVII, vectors, antibodies and methods
HRP20200583T1 (hr) * 2015-03-20 2020-07-10 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Protutijela koja neutraliziraju gp120 i njihova upotreba
MA45784A (fr) * 2016-07-29 2019-06-05 Juno Therapeutics Inc Anticorps anti-idiotypes dirigés contre anti-cd19 anticorps
TW201837174A (zh) * 2017-02-07 2018-10-16 日商第一三共股份有限公司 抗ｇｐｒｃ５ｄ抗體及包含該抗體之分子
WO2021113780A1 (en) 2019-12-06 2021-06-10 Juno Therapeutics, Inc. Anti-idiotypic antibodies to gprc5d-targeted binding domains and related compositions and methods

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2019527061A (ja) 2016-07-20 2019-09-26 ヤンセン ファーマシューティカ エヌ．ベー． 抗ｇｐｒｃ５ｄ抗体、ｇｐｒｃ５ｄとｃｄ３を結合する二重特異性抗原結合分子、及びその使用
WO2020148677A1 (en) 2019-01-18 2020-07-23 Janssen Biotech, Inc. Gprc5d chimeric antigen receptors and cells expressing the same

Also Published As

Publication number Publication date
IL299894A (en) 2023-03-01
CA3189562A1 (en) 2022-01-20
US12030937B2 (en) 2024-07-09
US20220064284A1 (en) 2022-03-03
WO2022013819A1 (en) 2022-01-20
CN115884987A (zh) 2023-03-31
EP4225801A1 (en) 2023-08-16
JP2023535684A (ja) 2023-08-21

Similar Documents

Publication Publication Date Title
KR102629403B1 (ko) Vista 항원 결합 분자
JP7649744B2 (ja) Ｂｔｎ３ａ結合タンパク質及びその使用
CN109988240B (zh) 抗gpc-3抗体及其用途
CA3059447A1 (en) Anti-pd-l1 antibody and use thereof
CN115505043A (zh) 特异性结合糖基化ceacam5的抗体
KR20250152073A (ko) 항체, 항원 결합 단편 및 사용 방법
US20230331840A1 (en) Cd22 antibody and application thereof
JP7797469B2 (ja) 抗ｋｌｋ２抗体に対する抗イディオタイプ抗体
TW202417496A (zh) 分離的抗原結合蛋白及其用途
CN114656566B (zh) 一种靶向cd47的抗体及其应用
CN115433277A (zh) 抗cd38兔重组单克隆抗体的制备及应用
WO2024012513A1 (en) Antibody, antigen-binding fragment thereof, and pharmaceutical use thereof
US12030937B2 (en) Anti-idiotypic antibodies against anti-GPRC5D antibodies
CN119604529A (zh) 抗体、其抗原结合片段及其药物用途
US20230094867A1 (en) Anti-idiotypic antibodies against anti-cd79b antibodies
WO2024131846A1 (en) Antibody, antigen-binding fragment thereof, and pharmaceutical use thereof
CN121866270A (zh) 抗gcc抗体、嵌合抗原受体及其用途
TW202436355A (zh) 抗原結合分子及使用方法
TW202511295A (zh) Ｃｔｌａ４／ｔｉｇｉｔ結合蛋白及其醫藥用途
CN116135885A (zh) 靶向cd73蛋白的融合蛋白
CN117285628A (zh) 抗vista抗体及其应用
CN121914265A (zh) 一种抗胃泌素释放肽前体的抗体及其应用
EA044327B1 (ru) Антитело к pd-l1 и его применение
BR112018067951B1 (pt) Anticorpo anti- transcrito 7 semelhante à imunoglobulina, composição farmacêutica e uso dos mesmos

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240617

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20240617

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20250603

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250827

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20251014

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20260114

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20260303

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20260401

R150 Certificate of patent or registration of utility model

Ref document number: 7844430

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150